Lung cancer is the most common cause of cancer death in both men and women in Western countries, with a 5-year survival rate of 15%, which is among the lowest of all cancers. The high mortality from lung cancer is due not only to the late stage diagnosis but also to the lack of effective treatments even for patients diagnosed with stage I lung cancer. Therefore, there is an urgent need to identify new markers for early diagnosis and prognosis that could serve to open novel therapeutic avenues. Proteomics can represent an important tool for the identification of biomarkers and therapeutic targets for lung cancer since DNA-based biomarkers did not prove to have adequate sensitivity, specificity, and reproducibility. In this paper we will describe studies focused on the identification of new diagnostic, prognostic, and predictive markers for lung cancer, using proteomics technologies.
Lung cancer patients have the highest mortality among patients with solid tumors worldwide and their prognosis is strictly stage-associated. However, only 15–20% of patients are diagnosed in stage I, since these early tumors are frequently asymptomatic. Early detection of lung cancer, which allows effective therapeutic intervention, is a promising approach to lowering its mortality rate. However, conventional diagnostic methods for lung cancer, such as chest X-ray and CT of the chest, produce high costs and potentially false-positive results. Thus, the discovery of highly sensitive, specific, noninvasive, and cost-effective lung cancer biomarkers combined with conventional approaches, such as X-rays, may improve the sensitivity of lung cancer screening. Herein, we summarize the most recent studies about the molecular pathology of lung cancer and discuss the advancements expected in the near future, including the potential biomarkers and liquid biopsy approaches for the detection of lung cancer in populations at risk of developing this disease.
21 November 2016 in International Journal of Clinical & Medical Microbiology
The Variola major, the virus that causes the smallpox, lethal virus in the 30% of the cases, was eraticated in 1979 in the human species, thanks to a capillary vaccination on global scale. Recently the Word Health Organization (WHO) declared that India and Southeast Asia are polio-free, really a great achivement since the vaccine for polio, an infectious desease that can cause paralysis, was certificated safe and useful only 60 years ago. The vaccine for the virus, responsible for hepatitis B infection HBV, is able to prevent 50% of all liver cancers. Human Papilloma Virus (HPV) have been correlated with the cervical cancer (genotypes 16 and 18 particularly oncogenic in humans): the USA Food and Drug Administration (FDA) in 2006 released the first vaccine against HPV. Finally, the ability of the immune system to recognize a tumor-associated antigen enables the development of a vaccine approach for therapeutic application and represents a main target of this field of research. Long years of research were required for busting new systems to fight cancer. Research is going to obtain the complete sequence by proteomics approaches, in order to achieve adequate antigen preparations that might be used to generate assays for a specific anticancer vaccine.